Stay updated with breaking news from Gel Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leading biotech company Assembly Biosciences has recently announced the selection of ABI-6250 as a promising candidate for the treatment of chronic hepatitis
Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Free Report) – HC Wainwright lifted their Q3 2023 earnings per share (EPS) estimates for shares of Sol-Gel Technologies in a report released on Monday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.24) per share for the quarter, up from their […]
Sol-Gel Technologies (NASDAQ:SLGL – Free Report) had its target price lowered by Raymond James from $9.00 to $7.00 in a research note released on Friday morning, Marketbeat Ratings reports. The firm currently has a strong-buy rating on the stock. Separately, HC Wainwright restated a buy rating and set a $19.00 price objective on shares of […]
Sol-Gel Technologies (NASDAQ:SLGL – Free Report) had its target price decreased by Raymond James from $10.00 to $9.00 in a report released on Wednesday morning, FlyOnTheWall reports. Separately, HC Wainwright reaffirmed a buy rating and set a $19.00 target price on shares of Sol-Gel Technologies in a research report on Wednesday, April 12th. Sol-Gel Technologies […]
Key Insights Sol-Gel Technologies' significant insider ownership suggests inherent interests in company's expansion...